Dr. Allison Kurian’s publication on recent chemotherapy trends featured in New York Times’ article about reducing use of chemotherapy for cancer treatment.

Genetic testing is vital for women with breast and ovarian cancers in order to determine the best treatment for each woman. Dr. Allison Kurian’s recent paper published on February 9th, 2021 is featured by Stanford Medicine’s Scope Blog to discuss the importance of genetic testing in greater detail.

Additional coverage of this paper can be found at: The ASCO Post | OncLive | MedScape

Dr. Chris Friese receives a $2 million grant from the National Cancer Institute to help University of Michigan Rogel Cancer Center researchers prepare the next generation of scientists focused on cancer care delivery.

A recent paper by Dr. Allison Kurian published in JAMA is highlighted by Michigan’s Rogel Cancer Center.

Dr. Allison Kurian featured in Oncology Times’ article promoting genetic testing for women with breast and ovarian cancers.

Dr. Allison Kurian’s new study about gaps in genetic testing for breast and ovarian cancers was published in the Journal of Clinical Oncology on April 10th, 2019. This population-based study of women with these cancers showed that 8% to 15% had prevalence of actionable pathogenic variants. Genetic testing gaps and disparities among these women are targets for improvement.

The new study about PCP involvement in breast cancer treatment decision-making by Lauren Wallner, PhD, MPH has been featured by Medscape.